SHC
Sotera Health CoPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 6 ▼ Two major shareholder-directors, GTCR Investment XI LLC and Warburg…
- Mar 6 ▼ 2 insiders sell $610.8M at $15.27
- Mar 26 Kurt M. Roth v. Sotera Health Company
- May 5 ▲ Sotera Health reported strong Q1 2026 results with revenue up 10.0%…
- May 11 Offering: Sotera Health Announces Secondary Offering of Common Stock
- May 13 ▼ 2 insiders sell $772.7M at $15.17
- May 15 ▼ Two major PE shareholders (Warburg Pincus and GTCR) sold a combined…
- May 15 ▼ Two major sponsors (Warburg Pincus and GTCR) sold a combined ~31.8M…
- Aug 6 ▲ Sotera Health reported Q2 2026 results with net revenues of $321.4M…
- Aug 7 ▼ 1 insider sell $2.8M at $18.84
- Aug 17 ▼ 1 insider sell $21.2M at $18.50
- Oct 14 ▼ JP Morgan downgrades
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $1.4B.
- InstitutionsBULLISH
Q3 2026: 38 added (0 new), 11 trimmed or exited.
- AnalystsBULLISH
12 of 15 rate it Buy or better. Median target $22.00 (+32%).
- Short sellersSTEADY
Short interest +2.1% to 16.44M shares. 7.5 days to cover, ≈5.8% of shares.
- TrendDOWNTREND
8% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JPMORGAN CHASE & CO | DOUBLED | $46.9M |
| Bank of New York Mellon Corp | ADD | $36.8M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $28.0M |
| Nuveen, LLC | DOUBLED | $27.1M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | $23.9M |
| BARCLAYS PLC | DOUBLED | $10.2M |
| SEI INVESTMENTS CO | DOUBLED | $7.7M |
| Quantinno Capital Management LP | ADD | $6.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
15 analystsPrice is inside the target range. Median implies +32%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 4, 2026 | JP Morgan MAINTAIN | Underweight |
| Nov 4, 2026 | Barclays MAINTAIN | Overweight |
| Oct 14, 2026 | JP Morgan DOWNGRADE | Underweight |
| Aug 7, 2026 | Citigroup MAINTAIN | Buy |
| Aug 7, 2026 | Barclays MAINTAIN | Overweight |
| Aug 7, 2026 | Piper Sandler REITERATE | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Petras Michael B. Jr. Executive Chairman Aug 17, 2026 | SELL | $15.7M |
Petras Michael B. Jr. Executive Chairman Aug 17, 2026 | SELL | $5.4M |
Rutz Michael P President of Sterigenics Aug 7, 2026 | SELL | $2.8M |
Lyons Jonathan M. Sr. Vice President, CFO Aug 5, 2026 | TAX W/H | $203.5K |
SHADER ALTON Chief Executive Officer May 26, 2026 | AWARD | 375,939 sh |
SHADER ALTON Chief Executive Officer May 26, 2026 | AWARD | 203,634 sh |
SHADER ALTON Chief Executive Officer May 26, 2026 | AWARD | 101,817 sh |
Wheadon David E. Director May 22, 2026 | AWARD | 14,970 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
18 filings · 5 bullish · 4 bearish · 9 neutral- NEUTRAL 8-KNov 3, 2026
Sotera Health reported Q3 2026 net revenues of $324.9M, up 4.4% YoY, and Adjusted EPS of $0.29, a…
The reaffirmed full-year guidance suggests management sees no material change in business momentum. Monitor the Q4 2026 earnings for any revision to the 2027 outlook, particularly given the Nordion…
- BULLISH PRESS-RELEASENov 3, 2026
Sotera Health reported Q3 2026 adjusted EPS of $0.29, beating the $0.27 consensus by 7.4%, and…
The reaffirmed full-year guidance and strong Sterigenics/Nelson Labs growth suggest operational momentum is intact. Watch for any updates on EO litigation developments and Nordion's Co-60 harvest…
- NEUTRAL SC 13GOct 30, 2026
Vanguard Capital Management LLC filed a Schedule 13G disclosing a 5.12% passive stake in Sotera…
Vanguard's new 5%+ stake is consistent with index fund rebalancing and is not a conviction signal. The cross-filing context shows Sachem Head Capital Management fully exited 21 days prior, which may…
- NEUTRAL INST-CLUSTEROct 21, 2026
Three asset managers added to their Sotera Health positions in Q3 2026, with aggregate holdings…
The buying cluster is small in dollar terms and comes from routine asset managers, not high-conviction funds. Monitor upcoming 13F filings for larger institutional moves or insider activity to…
All SHC filing & press-release reports (18)
- 8-K reportNov 3, 2026
- PRESS-RELEASE reportNov 3, 2026
- SC 13G reportOct 30, 2026
- INST-CLUSTER reportOct 21, 2026
- SC 13G/A reportOct 9, 2026
- 8-K reportAug 14, 2026
- INST-CLUSTER reportAug 9, 2026
- 144 reportAug 7, 2026
- 8-K reportAug 6, 2026
- 3 reportMay 27, 2026
- 8-K reportMay 20, 2026
- CLUSTER reportMay 15, 2026
- CLUSTER reportMay 15, 2026
- 8-K reportMay 5, 2026
- PRESS-RELEASE reportMay 5, 2026
- PRESS-RELEASE reportApr 21, 2026
- DEFA14A reportApr 8, 2026
- CLUSTER reportMar 6, 2026